Caplyta Is Acquired by Johnson & Johnson

This week, Johnson & Johnson made headlines by revealing its $14.6 billion acquisition of Intra-Cellular Therapies. The New York City-based biotech company specializes in developing products for the central nervous system. It is most well-known for its FDA-approved drug, Caplyta.…